Exact Mass: 626.315

Red chlorophyll catabolite

C35H38N4O7 (626.274)

2-[4,7,10-Tris(carboxymethyl)-6-[4-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]butyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

C27H42N6O11 (626.2911)

PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C33H55O9P (626.3584)

PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0)

C33H55O9P (626.3584)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C33H55O9P (626.3584)

PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0)

C33H55O9P (626.3584)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C33H55O9P (626.3584)

PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0)

C33H55O9P (626.3584)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C33H55O9P (626.3584)

PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0)

C33H55O9P (626.3584)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C33H55O9P (626.3584)

PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0)

C33H55O9P (626.3584)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C33H55O9P (626.3584)

PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0)

C33H55O9P (626.3584)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Bonaspectin B

C35H46O10 (626.3091)

Xylocarpin G

C34H42O11 (626.2727)

Manauealide A

C32H47ClO10 (626.2858)

Tricalysioside D

C31H46O13 (626.2938)

Swietemahonin F

C34H42O11 (626.2727)

Leucasperoside B

C32H50O12 (626.3302)

NK 30424A

C30H46N2O10S (626.2873)

Phlomisoside II

C32H50O12 (626.3302)

Humilinolide E

C34H42O11 (626.2727)

Spumigin B2

C31H42N6O8 (626.3064)

Hanburinone

C34H42O11 (626.2727)

5,6-Dehydroguiachrysine

C40H42N4O3 (626.3257)

nimbolinin B

C35H46O10 (626.3091)

Chisonimbolinin G

C35H46O10 (626.3091)

C40H50O6

C40H50O6 (626.3607)

1beta-acetoxy-9alpha-benzoyloxy-8beta-(beta-furancarbonyloxy)-6alpha-hydroxy-2beta-(alpha-methylbutanoyloxy)-beta-dihydroagarofuran

C34H42O11 (626.2727)

beta-Edcyson-3-p-coumarat

C36H50O9 (626.3455)

C35H46O10

C35H46O10 (626.3091)

(6E,10Z)-12-acetoxy-5-hydroxy-beta-nerolidol-5-O-beta-D-tetraacetylglucopyranoside

C31H46O13 (626.2938)

dregeana-1

C34H42O11 (626.2727)

5-((S)-7-Hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isochinolylmethyl)-4-(4-((S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isochinolylmethyl]-phenoxy)-2-methoxy-phenol|5-((S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isoquinolylmethyl)-4-(4-((S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isoquinolylmethyl]-phenoxy)-2-methoxy-phenol|Magnolamin|Magnolamine

C37H42N2O7 (626.2992)

phorbaside F

C32H47ClO10 (626.2858)

genkwanine K

C34H42O11 (626.2727)

deoxylosyl-anodendrosin G

C31H46O13 (626.2938)

C37H42N2O7

C37H42N2O7 (626.2992)

Polypodin B2-cinnamat

C36H50O9 (626.3455)

Chamaepitin

C31H46O13 (626.2938)

viticosterone E 22-O-benzoate

C36H50O9 (626.3455)

3,12-diacetyl-7-phenylacetyl 19-acetoxyingol

C34H42O11 (626.2727)

Xylogranatin B

C34H42O11 (626.2727)

pyrrhoxanthin

C40H50O6 (626.3607)

cipadesin M

C35H46O10 (626.3091)

Anodendrosin A

C31H46O13 (626.2938)

6-chloro-triacetyl-disidein

C37H51ClO6 (626.3374)

2-Cinnamoyl-(2beta,3beta,5beta,20R,22R,24S)-2,3,5,14,20,22,24-Heptahydroxycholest-7-en-6-one|Polypodin C2-cinnamat

C36H50O9 (626.3455)

C31H46O13

C31H46O13 (626.2938)

(8aR,8aR,10aR,10aR)-1,2-bis(2-hydroxy-1-isopropyl-8a,10a-dimethyl-7,8,8a,9,10,10a-hexahydrobenzo[f]azulene-3,6-dion-5-yl)-ethane|radianspene M

C40H50O6 (626.3607)

3beta-benzoyloxy-5alpha,8alpha-diacetoxy-15beta-hydroxy-7beta-propanoyloxyjatropha-6(17),11E-diene-9,14-dione

C34H42O11 (626.2727)

C36H50O9

C36H50O9 (626.3455)

cochinchinoid A

C36H50O9 (626.3455)

sapinsignoid C

C36H50O9 (626.3455)

milbemycin alpha20

C36H50O9 (626.3455)

Me glycoside,3,4,6-tribenzyl-2-O-alpha-D-Mannopyranosyl-D-mannose

C34H42O11 (626.2727)

(4aR,5S,6R,8aS)-5-[2-(2,5-dihydro-5-oxofuran-3-yl)ethyl]-3,4,4a,5,6,7,8,8a-octahydro-5,6,8a-trimethylnaphthalene-1-carboxylic acid (6-O-D-apio-beta-D-glucopyranosyl ester)|caseariaside C|cis-cleroda-3,13-diene-15,18-dioic acid 15,16-lactone 18-(6-O-beta-apiofuranosyl-beta-D-glucopyranosyl) ester

C31H46O13 (626.2938)

[DES-TYR1 ]-EC-CASOMORPHIN

C32H46N6O7 (626.3428)

piperchabamide H

C38H46N2O6 (626.3356)

euphornin D

C35H46O10 (626.3091)

Chenabinol

C37H42N2O7 (626.2992)

Asp His Leu Thr Gln

C26H42N8O10 (626.3024)

Phainanoid A

C38H42O8 (626.288)

C34H42O11_7,11-Methano-2H-cycloocta[3,4]benzo[1,2-c]pyran-8-acetic acid, alpha-(acetyloxy)-4-(3-furanyl)-1,4,4a,5,6,6a,7,8,9,10,11,12-dodecahydro-11-hydroxy-4a,7,9,9-tetramethyl-10-[[(2E)-2-methyl-1-oxo-2-buten-1-yl]oxy]-2,13-dioxo-, methyl ester

C34H42O11 (626.2727)

Glu His Arg Trp

C28H38N10O7 (626.2925)

Glu His Trp Arg

C28H38N10O7 (626.2925)

Glu Arg His Trp

C28H38N10O7 (626.2925)

Glu Arg Trp His

C28H38N10O7 (626.2925)

Glu Trp His Arg

C28H38N10O7 (626.2925)

Glu Trp Arg His

C28H38N10O7 (626.2925)

Phe Phe Lys Trp

C35H42N6O5 (626.3217)

Phe Phe Gln Trp

C34H38N6O6 (626.2853)

Phe Phe Trp Lys

C35H42N6O5 (626.3217)

Phe Phe Trp Gln

C34H38N6O6 (626.2853)

Phe Lys Phe Trp

C35H42N6O5 (626.3217)

Phe Lys Trp Phe

C35H42N6O5 (626.3217)

Phe Gln Phe Trp

C34H38N6O6 (626.2853)

Phe Gln Trp Phe

C34H38N6O6 (626.2853)

Phe Trp Phe Lys

C35H42N6O5 (626.3217)

Phe Trp Phe Gln

C34H38N6O6 (626.2853)

Phe Trp Lys Phe

C35H42N6O5 (626.3217)

Phe Trp Gln Phe

C34H38N6O6 (626.2853)

His Glu Arg Trp

C28H38N10O7 (626.2925)

His Glu Trp Arg

C28H38N10O7 (626.2925)

His Arg Glu Trp

C28H38N10O7 (626.2925)

His Arg Trp Glu

C28H38N10O7 (626.2925)

His Val Trp Trp

C33H38N8O5 (626.2965)

His Trp Glu Arg

C28H38N10O7 (626.2925)

His Trp Arg Glu

C28H38N10O7 (626.2925)

His Trp Val Trp

C33H38N8O5 (626.2965)

His Trp Trp Val

C33H38N8O5 (626.2965)

Lys Phe Phe Trp

C35H42N6O5 (626.3217)

Lys Phe Trp Phe

C35H42N6O5 (626.3217)

Lys Met Trp Tyr

C31H42N6O6S (626.2886)

Lys Met Tyr Trp

C31H42N6O6S (626.2886)

Lys Trp Phe Phe

C35H42N6O5 (626.3217)

Lys Trp Met Tyr

C31H42N6O6S (626.2886)

Lys Trp Tyr Met

C31H42N6O6S (626.2886)

Lys Tyr Met Trp

C31H42N6O6S (626.2886)

Lys Tyr Trp Met

C31H42N6O6S (626.2886)

Met Lys Trp Tyr

C31H42N6O6S (626.2886)

Met Lys Tyr Trp

C31H42N6O6S (626.2886)

Met Trp Lys Tyr

C31H42N6O6S (626.2886)

Met Trp Tyr Lys

C31H42N6O6S (626.2886)

Met Tyr Lys Trp

C31H42N6O6S (626.2886)

Met Tyr Trp Lys

C31H42N6O6S (626.2886)

Gln Phe Phe Trp

C34H38N6O6 (626.2853)

Gln Phe Trp Phe

C34H38N6O6 (626.2853)

Gln Trp Phe Phe

C34H38N6O6 (626.2853)

Arg Glu His Trp

C28H38N10O7 (626.2925)

Arg Glu Trp His

C28H38N10O7 (626.2925)

Arg His Glu Trp

C28H38N10O7 (626.2925)

Arg His Trp Glu

C28H38N10O7 (626.2925)

Arg Trp Glu His

C28H38N10O7 (626.2925)

Arg Trp His Glu

C28H38N10O7 (626.2925)

Val His Trp Trp

C33H38N8O5 (626.2965)

Val Trp His Trp

C33H38N8O5 (626.2965)

Val Trp Trp His

C33H38N8O5 (626.2965)

Trp Glu His Arg

C28H38N10O7 (626.2925)

Trp Glu Arg His

C28H38N10O7 (626.2925)

Trp Phe Phe Lys

C35H42N6O5 (626.3217)

Trp Phe Phe Gln

C34H38N6O6 (626.2853)

Trp Phe Lys Phe

C35H42N6O5 (626.3217)

Trp Phe Gln Phe

C34H38N6O6 (626.2853)

Trp His Glu Arg

C28H38N10O7 (626.2925)

Trp His Arg Glu

C28H38N10O7 (626.2925)

Trp His Val Trp

C33H38N8O5 (626.2965)

Trp His Trp Val

C33H38N8O5 (626.2965)

Trp Lys Phe Phe

C35H42N6O5 (626.3217)

Trp Lys Met Tyr

C31H42N6O6S (626.2886)

Trp Lys Tyr Met

C31H42N6O6S (626.2886)

Trp Met Lys Tyr

C31H42N6O6S (626.2886)

Trp Met Tyr Lys

C31H42N6O6S (626.2886)

Trp Gln Phe Phe

C34H38N6O6 (626.2853)

Trp Arg Glu His

C28H38N10O7 (626.2925)

Trp Arg His Glu

C28H38N10O7 (626.2925)

Trp Val His Trp

C33H38N8O5 (626.2965)

Trp Val Trp His

C33H38N8O5 (626.2965)

Trp Trp His Val

C33H38N8O5 (626.2965)

Trp Trp Val His

C33H38N8O5 (626.2965)

Trp Tyr Lys Met

C31H42N6O6S (626.2886)

Trp Tyr Met Lys

C31H42N6O6S (626.2886)

Tyr Lys Met Trp

C31H42N6O6S (626.2886)

Tyr Lys Trp Met

C31H42N6O6S (626.2886)

Tyr Met Lys Trp

C31H42N6O6S (626.2886)

Tyr Met Trp Lys

C31H42N6O6S (626.2886)

Tyr Trp Lys Met

C31H42N6O6S (626.2886)

Tyr Trp Met Lys

C31H42N6O6S (626.2886)

EKLTH

C27H46N8O9 (626.3388)

PI(20:1(11Z)/0:0)

C29H55O12P (626.3431)

LPI 20:1

C29H55O12P (626.3431)

ST 36:8;O9

C36H50O9 (626.3455)

Stelleracin E

C35H46O10 (626.3091)

LITHIUM TANTALUM TERT-BUTOXIDE

C24H54LiO6Ta (626.356)

2-dodecylcyclopenta-1,3-diene,zirconium(4+),dichloride

C34H58Cl2Zr (626.2962)

guamecycline

C29H38N8O8 (626.2812)

C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic

benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid,propane-1,2-diol

C28H50O15 (626.315)

3-[2-[[3-(2-carboxyethyl)-5-[(3-ethyl-4-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methylpyrrol-3-yl]propanoic acid,hydrochloride

C33H43ClN4O6 (626.2871)

TRIS(N-TERT-BUTYL-3,5-DIMETHYLANILINO)MOLYBDENUM(III)

C36H54MoN3 (626.3372)

(2R)-2,6-diaminohexanoic acid; (2R,4S)-2-({[(5R)-5-amino-5-carboxypentyl]carbamoyl}(2-phenylacetamido)methyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid

C28H46N6O8S (626.3098)

Primary fluorescent chlorophyll catabolite(2-)

C35H38N4O7-2 (626.274)

3-[(3S,4S,5Z)-5-[(4-ethenyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methylidene]-2-[(2Z)-2-[(3-ethyl-5-formyl-4-methyl-1H-pyrrol-2-yl)methylidene]-4-hydroxy-5-methoxycarbonyl-3-methyl-1H-cyclopenta[b]pyrrol-6-yl]-4-methyl-3,4-dihydropyrrol-3-yl]propanoic acid

C35H38N4O7 (626.274)

3-[(21S,22S)-12-(dihydroxymethyl)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-17,19,21-trimethyl-11-propyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid

C36H42N4O6 (626.3104)

PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C33H55O9P (626.3584)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0)

C33H55O9P (626.3584)

PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C33H55O9P (626.3584)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0)

C33H55O9P (626.3584)

PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C33H55O9P (626.3584)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0)

C33H55O9P (626.3584)

PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C33H55O9P (626.3584)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0)

C33H55O9P (626.3584)

PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C33H55O9P (626.3584)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0)

C33H55O9P (626.3584)

PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C33H55O9P (626.3584)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0)

C33H55O9P (626.3584)

2-[[(2R)-3-acetyloxy-2-[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-2-acetyloxy-3-[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-3-acetyloxy-2-[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-2-acetyloxy-3-[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-3-acetyloxy-2-[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-2-acetyloxy-3-[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-3-acetyloxy-2-[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-2-acetyloxy-3-[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-15-[3-[(Z)-pent-2-enyl]oxiran-2-yl]pentadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

2-[[(2R)-2-acetyloxy-3-[(4Z,7Z,10Z,13Z)-15-[3-[(Z)-pent-2-enyl]oxiran-2-yl]pentadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H53NO9P+ (626.3458)

euphornin L

C35H46O10 (626.3091)

A macrocyclic diterpenoid isolated from Euphorbia helioscopia and has been shown to exhibit cytotoxicity against HL-60 cell lines.

ciguatoxin HIJKLM cyclic acetal

C32H50O12 (626.3302)

3-[(3S,4S,5Z)-5-[(4-ethenyl-5-hydroxy-3-methyl-1H-pyrrol-2-yl)methylidene]-2-[2-[(3-ethyl-5-formyl-4-methyl-1H-pyrrol-2-yl)methyl]-5-methoxycarbonyl-3-methyl-4-oxo-1H-cyclopenta[b]pyrrol-6-yl]-4-methyl-3,4-dihydropyrrol-3-yl]propanoic acid

C35H38N4O7 (626.274)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-icos-11-enoate

C29H55O12P (626.3431)

Dgdg O-8:0_6:0

C29H54O14 (626.3513)

Dgdg O-9:0_5:0

C29H54O14 (626.3513)

Smgdg O-16:1_4:0

C29H54O12S (626.3336)

Smgdg O-18:1_2:0

C29H54O12S (626.3336)

Smgdg O-15:1_5:0

C29H54O12S (626.3336)

Smgdg O-14:1_6:0

C29H54O12S (626.3336)

Smgdg O-13:1_7:0

C29H54O12S (626.3336)

Smgdg O-17:1_3:0

C29H54O12S (626.3336)

Dgdg O-10:0_4:0

C29H54O14 (626.3513)

Dgdg O-11:0_3:0

C29H54O14 (626.3513)

Dgdg O-12:0_2:0

C29H54O14 (626.3513)

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C32H51O10P (626.322)

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate

C28H50O15 (626.315)

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] heptanoate

C28H50O15 (626.315)

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] octanoate

C28H50O15 (626.315)

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

C28H50O15 (626.315)

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

C28H50O15 (626.315)

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate

C28H51O13P (626.3067)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tetradec-9-enoate

C28H51O13P (626.3067)

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C32H51O10P (626.322)

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate

C28H51O13P (626.3067)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

C28H51O13P (626.3067)

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-heptadec-9-enoate

C28H51O13P (626.3067)

[(2S,3S,6S)-6-[(2S)-2,3-di(decanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C29H54O12S (626.3336)

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C32H51O10P (626.322)

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C32H51O10P (626.322)

Primary fluorescent chlorophyll catabolite(2-)

C35H38N4O7 (626.274)

Dianion of primary fluorescent chlorophyll catabolite.

1-(11Z-eicosenoyl)-glycero-3-phospho-(1-myo-inositol)

C29H55O12P (626.3431)

PI(19:1)

C28H51O13P (626.3067)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

SMGDG O-20:1

C29H54O12S (626.3336)

SQDG 20:0

C29H54O12S (626.3336)

DGMG 14:0

C29H54O14 (626.3513)

DGGA 23:4;O

C32H50O12 (626.3302)

PA O-30:6;O2

C33H55O9P (626.3584)

PA P-18:1/12:4;O2

C33H55O9P (626.3584)

PA 18:2/12:3;O

C33H55O9P (626.3584)

PA 20:2/9:4;O2

C32H51O10P (626.322)

PA 20:4/8:3;O3

C31H47O11P (626.2856)

PA 20:5/8:2;O3

C31H47O11P (626.2856)

PA 20:5/9:1;O2

C32H51O10P (626.322)

PA 22:2/8:3;O

C33H55O9P (626.3584)

PA 22:4/7:2;O2

C32H51O10P (626.322)

PA 22:4/8:1;O

C33H55O9P (626.3584)

PA 28:7;O3

C31H47O11P (626.2856)

PA 29:6;O2

C32H51O10P (626.322)

PA 30:5;O

C33H55O9P (626.3584)

PG O-16:0/7:2;O3

C29H55O12P (626.3431)

PG O-23:2;O3

C29H55O12P (626.3431)

PG 14:0/8:2;O3

C28H51O13P (626.3067)

PG 14:0/9:1;O2

C29H55O12P (626.3431)

PG 18:0/5:1;O2

C29H55O12P (626.3431)

PG 18:4/7:3;O

C31H47O11P (626.2856)

PG 22:2;O3

C28H51O13P (626.3067)

PG 23:1;O2

C29H55O12P (626.3431)

PG 25:7;O

C31H47O11P (626.2856)

PG 22:5/4:1

C32H51O10P (626.322)

PG 22:6/4:0

C32H51O10P (626.322)

PG 26:6

C32H51O10P (626.322)

PG 4:0_22:6

C32H51O10P (626.322)

PI O-16:0/4:1

C29H55O12P (626.3431)

PI O-16:1/4:0

C29H55O12P (626.3431)

PI O-18:1/2:0

C29H55O12P (626.3431)

PI O-20:1

C29H55O12P (626.3431)

PI P-16:0/4:0

C29H55O12P (626.3431)

PI P-16:0/4:0 or PI O-16:1/4:0

C29H55O12P (626.3431)

PI P-18:0/2:0

C29H55O12P (626.3431)

PI P-18:0/2:0 or PI O-18:1/2:0

C29H55O12P (626.3431)

PI P-20:0

C29H55O12P (626.3431)

PI P-20:0 or PI O-20:1

C29H55O12P (626.3431)

PI 14:1/4:1;O

C27H47O14P (626.2703)

PI 18:2;O

C27H47O14P (626.2703)

PI 15:0/4:1

C28H51O13P (626.3067)

PI 15:1/4:0

C28H51O13P (626.3067)

PI 17:1/2:0

C28H51O13P (626.3067)

PI 19:1

C28H51O13P (626.3067)

PEth 28:5;O

C33H55O9P (626.3584)

PM 29:5;O

C33H55O9P (626.3584)

ST 25:3;O7;GlcA

C31H46O13 (626.2938)

ST 26:2;O6;GlcA

C32H50O12 (626.3302)

ST 29:7;O4;GlcA

C35H46O10 (626.3091)

ST 25:4;O8;Hex

C31H46O13 (626.2938)

ST 26:3;O7;Hex

C32H50O12 (626.3302)

15-[1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylbut-2-enoate

C34H42O11 (626.2727)

(1r,2r,4s,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

(1s,6s,7s,10s,11r,12r,14s,15s,16r,18s)-18-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

3-[5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-(1-hydroxyethyl)-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione

C32H47ClO10 (626.2858)

(1s,3as,5ar,7s,8s,9ar,9br,11ar)-3a,8-dihydroxy-9a,11a-dimethyl-5-oxo-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C36H50O9 (626.3455)

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

(1s,2r,4s,5s,9r,10r,13r,14r,15r,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 3,5-bis(3-methylbut-2-en-1-yl)-4-[(2,4,6-trihydroxy-3,5-dimethoxycyclohexyl)oxy]benzoate

C31H46O13 (626.2938)

2-amino-3-{[(7z)-10-hydroxy-12-[(2e)-7-hydroxy-8-(2-hydroxy-6-oxo-4,5-dihydro-3h-pyridin-4-yl)-4-methyl-5-oxooct-2-en-2-yl]-9-methoxy-11-methyl-2-oxo-1-oxacyclododec-7-en-4-yl]sulfanyl}propanoic acid

C30H46N2O10S (626.2873)

17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

C35H46O10 (626.3091)

(1r,2r,4s,5r,9r,10r,13r,14s,15s,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e)-6-oxotetradeca-2,4-dienoate

C36H50O9 (626.3455)

(1r,5r,6r,13r,16s)-16-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(2s,4as,4br,7r,10ar)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one

C32H50O12 (626.3302)

(1r,2s,3r,4ar,5s,6r,8s,8ar)-5-[(2s,3as,5s,6ar)-5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl (2r,3s)-3-(acetyloxy)-2-methylbutanoate

C31H46O13 (626.2938)

10,10'-dihydroxy-2,2'-diisopropyl-4b,4'b,8,8,8',8'-hexamethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah-[4,4'-biphenanthrene]-3,3',9,9'-tetrone

C40H50O6 (626.3607)

5-carbamimidamido-2-({[1-(2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl)-4-methylpyrrolidin-2-yl](hydroxy)methylidene}amino)pentanoic acid

C31H42N6O8 (626.3064)

(2r,3r,4s,5s)-2-(3,5-dimethoxy-4-{[(2s)-1-(3,4,5-trimethoxyphenyl)propan-2-yl]oxy}phenyl)-3,4-dimethyl-5-(3,4,5-trimethoxyphenyl)oxolane

C35H46O10 (626.3091)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one

C32H50O12 (626.3302)

4-[5-(2,3-dihydroxy-3-methylbutyl)-12-hydroxy-16-methoxy-8,8,21,21-tetramethyl-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

C34H42O11 (626.2727)

(1r,2r,4r,6s,8r,11r,12r,13s,16s,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,15-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

(1s)-1-{[2-hydroxy-3-(4-{[(1r)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenoxy)-4-methoxyphenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C37H42N2O7 (626.2992)

2,3,5-trihydroxy-4,6-dimethoxycyclohexyl 3,5-bis(3-methylbut-2-en-1-yl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoate

C31H46O13 (626.2938)

[(2s,3s,3ar,4s,5r,6s,6as,7r,8r,10r,10ar,10bs)-7-(benzoyloxy)-3,3a,4,5,6,8,10a-heptahydroxy-2,10-dimethyl-8-(prop-1-en-2-yl)-decahydrocyclohexa[e]azulen-5-yl]methyl benzoate

C34H42O11 (626.2727)

(1s,3as,5as,7r,8r,9ar,9bs,11ar)-3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl (2e)-3-phenylprop-2-enoate

C36H50O9 (626.3455)

(4bs,4'bs,8as,8'as)-10,10'-dihydroxy-2,2'-diisopropyl-4b,4'b,8,8,8',8'-hexamethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah-[4,4'-biphenanthrene]-3,3',9,9'-tetrone

C40H50O6 (626.3607)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-2-{[(2s,4as,8ar)-5-[2-(furan-3-yl)ethyl]-1,1,4a,6-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H50O12 (626.3302)

17-{[6-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-17-(hydroxymethyl)-12-methyl-8-oxapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-5-en-7-one

C31H46O13 (626.2938)

(1r,2r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

n-[(3r,4s,7s,10r,15as)-5,8-dihydroxy-7,10-bis(1h-indol-3-ylmethyl)-3-methyl-1,11-dioxo-3h,4h,7h,10h,13h,14h,15h,15ah-pyrrolo[2,1-c]1-oxa-4,7,10-triazacyclotridecan-4-yl]propanimidic acid

C34H38N6O6 (626.2853)

(1s)-4-[(3e,5e,7e,9e,11e)-12-[(2r)-4-[(1e)-2-[(1s,4s,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]ethenyl]-5-oxo-2h-furan-2-yl]-3,10-dimethyldodeca-3,5,7,9,11-pentaen-1-yn-1-yl]-3,5,5-trimethylcyclohex-3-en-1-yl acetate

C40H50O6 (626.3607)

(1s,2r,4s,5r,6s,7r,8r,9s,12r)-5-(acetyloxy)-7-(benzoyloxy)-12-hydroxy-2,6,10,10-tetramethyl-4-{[(2r)-2-methylbutanoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl furan-3-carboxylate

C34H42O11 (626.2727)

17,19-bis(acetyloxy)-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

C35H46O10 (626.3091)

2-(3,5-dimethoxy-4-{[1-(3,4,5-trimethoxyphenyl)propan-2-yl]oxy}phenyl)-3,4-dimethyl-5-(3,4,5-trimethoxyphenyl)oxolane

C35H46O10 (626.3091)

(4as,4'as,10as,10'as)-5,5'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,10ah,10'ah-[9,9'-biphenanthrene]-6,6',10,10'-tetrone

C40H50O6 (626.3607)

(1s,3as,5as,7r,8s,9ar,9bs,11ar)-3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-[(2r,3r,5s)-2,3,5-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl (2e)-3-phenylprop-2-enoate

C36H50O9 (626.3455)

(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl (4ar,5s,6r,8as)-5,6,8a-trimethyl-5-[2-(5-oxo-2h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylate

C31H46O13 (626.2938)

(1s,2r,4s,5r,9r,10r,13r,14s,15s,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2z)-2-methylbut-2-enoate

C34H42O11 (626.2727)

2-amino-3-({10-hydroxy-12-[7-hydroxy-8-(2-hydroxy-6-oxo-4,5-dihydro-3h-pyridin-4-yl)-4-methyl-5-oxooct-2-en-2-yl]-9-methoxy-11-methyl-2-oxo-1-oxacyclododec-7-en-4-yl}sulfanyl)propanoic acid

C30H46N2O10S (626.2873)

(1r,6r,7r,10r,11s,12s,14r,15s,16s,18r)-14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(1r,2r,4s,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

2-hydroxy-5-(2-{2-hydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl}ethyl)-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

C40H50O6 (626.3607)

(1s,3r,4r,5s,9s,13r,14s)-3-[(2r,5r)-5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-[(1s)-1-hydroxyethyl]-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione

C32H47ClO10 (626.2858)

(1r,6r,7r,10r,11s,12s,14r,15s,16s,18r)-18-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(2z)-4-[(1r,2r,15s,16r,17r,19s)-5-[(2r)-2,3-dihydroxy-3-methylbutyl]-12-hydroxy-16-methoxy-8,8,21,21-tetramethyl-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

C34H42O11 (626.2727)

(1r,2r,5s,6s,8r,10s,11s,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-6-(furan-3-yl)-1,5,11,16-tetramethyl-7-oxo-9,14-dioxahexacyclo[11.6.1.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰.0¹⁶,²⁰]icosan-12-yl 2-methylbutanoate

C35H46O10 (626.3091)

(1'r,2r,4's,5s,6r,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl (2e)-2-methylbut-2-enoate

C36H50O9 (626.3455)

(1s,3r,4s,5s,9r,13s,14r)-3-[(2s,5r)-5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-[(1s)-1-hydroxyethyl]-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione

C32H47ClO10 (626.2858)

(1s,2s,3ar,4s,5s,9r,11r,13as)-3a,4,9,11-tetrakis(acetyloxy)-2,5,8,8,12-pentamethyl-1h,2h,3h,4h,5h,9h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate

C35H46O10 (626.3091)

(6r,7r,10r,11s,12s,14r,15r,18r)-14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(1r,2r,4s,5s,9r,10r,13s,14s,15s,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

1-[(4-{4-hydroxy-2-[(7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-5-methoxyphenoxy}phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C37H42N2O7 (626.2992)

(1s)-1-{[4-(4-hydroxy-2-{[(1s)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-methoxyphenoxy)phenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C37H42N2O7 (626.2992)

16-[1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylbut-2-enoate

C34H42O11 (626.2727)

18-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl 2-methylbut-2-enoate

C34H42O11 (626.2727)

5-[(benzoyloxy)methyl]-3,3a,4,5,6,8,10a-heptahydroxy-2,10-dimethyl-8-(prop-1-en-2-yl)-decahydrocyclohexa[e]azulen-7-yl benzoate

C34H42O11 (626.2727)

(1r,6s,7s,10s,11s,12r,14r,15r,16s,18s)-14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl (2z)-2-methylbut-2-enoate

C34H42O11 (626.2727)

3a,8-dihydroxy-9a,11a-dimethyl-5-oxo-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl 3-(4-hydroxyphenyl)prop-2-enoate

C36H50O9 (626.3455)

{[(1s,4e,6r,8s,9s,10e,12s,13r,14s,16r,20s)-3,6,13,20-tetrahydroxy-8,14,19-trimethoxy-20-(methoxycarbonyl)-4,10,12,16-tetramethyl-21-oxo-2-azabicyclo[16.2.1]henicosa-2,4,10,18-tetraen-9-yl]oxy}methanimidic acid

C30H46N2O12 (626.3051)

3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl 3-phenylprop-2-enoate

C36H50O9 (626.3455)

(2r)-2-amino-3-{[(4r,7e,9r,10r,11r,12r)-10-hydroxy-12-[(2z,4r,7s)-7-hydroxy-8-(2-hydroxy-6-oxo-4,5-dihydro-3h-pyridin-4-yl)-4-methyl-5-oxooct-2-en-2-yl]-9-methoxy-11-methyl-2-oxo-1-oxacyclododec-7-en-4-yl]sulfanyl}propanoic acid

C30H46N2O10S (626.2873)

3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-(2,3,5-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl 3-phenylprop-2-enoate

C36H50O9 (626.3455)

5-(acetyloxy)-7-(benzoyloxy)-12-hydroxy-2,6,10,10-tetramethyl-4-[(2-methylbutanoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl furan-3-carboxylate

C34H42O11 (626.2727)

4-{12-[4-(2-{4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl}ethenyl)-5-oxo-2h-furan-2-yl]-3,10-dimethyldodeca-3,5,7,9,11-pentaen-1-yn-1-yl}-3,5,5-trimethylcyclohex-3-en-1-yl acetate

C40H50O6 (626.3607)

(2z)-3-[(1r,2s,3s,4r)-2-(2h-1,3-benzodioxol-5-yl)-4-[(5e)-6-(2h-1,3-benzodioxol-5-yl)hex-5-en-1-yl]-3-(piperidine-1-carbonyl)cyclobutyl]-1-(piperidin-1-yl)prop-2-en-1-one

C38H46N2O6 (626.3356)

8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5-{5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl}-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl 3-(acetyloxy)-2-methylbutanoate

C31H46O13 (626.2938)

14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl 2-methylbut-2-enoate

C34H42O11 (626.2727)

4,21',24'-trihydroxy-5,11',13',22'-tetramethyl-6-(4-methylpent-2-en-2-yl)-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraene-2',18'-dione

C36H50O9 (626.3455)

5,5'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,10ah,10'ah-[9,9'-biphenanthrene]-6,6',10,10'-tetrone

C40H50O6 (626.3607)

17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,15-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

C35H46O10 (626.3091)

6-{3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-(benzoyloxy)-6-hydroxy-2-methylheptan-2-yl acetate

C36H50O9 (626.3455)

3-[2-(2h-1,3-benzodioxol-5-yl)-4-[6-(2h-1,3-benzodioxol-5-yl)hex-5-en-1-yl]-3-(piperidine-1-carbonyl)cyclobutyl]-1-(piperidin-1-yl)prop-2-en-1-one

C38H46N2O6 (626.3356)

(2r,3r,4r,5s)-2-(3,5-dimethoxy-4-{[(2s)-1-(3,4,5-trimethoxyphenyl)propan-2-yl]oxy}phenyl)-3,4-dimethyl-5-(3,4,5-trimethoxyphenyl)oxolane

C35H46O10 (626.3091)

(2r)-5-carbamimidamido-2-({[(2s,4s)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl]-4-methylpyrrolidin-2-yl](hydroxy)methylidene}amino)pentanoic acid

C31H42N6O8 (626.3064)

(1s,2r,4s,5r,9r,10r,13r,14s,15s,17r)-15-[(1s)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(1'r,2r,4s,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,20'r,21'r,24's)-4,21',24'-trihydroxy-5,11',13',22'-tetramethyl-6-[(2e)-4-methylpent-2-en-2-yl]-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraene-2',18'-dione

C36H50O9 (626.3455)

butyl (6r)-6-[(1r,3ar,5ar,9as,11s,11ar)-11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C36H50O9 (626.3455)

(1s,2s,3ar,4r,5s,9r,11r,13as)-3a,4,9,11-tetrakis(acetyloxy)-2,5,8,8,12-pentamethyl-1h,2h,3h,4h,5h,9h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate

C35H46O10 (626.3091)

(2s,4as,4br,7r,10ar)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one

C32H50O12 (626.3302)

3a,4,9,11-tetrakis(acetyloxy)-2,5,8,8,12-pentamethyl-1h,2h,3h,4h,5h,9h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate

C35H46O10 (626.3091)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 3,5-bis(3-methylbut-2-en-1-yl)-4-{[(1r,2r,3s,4r,5r,6s)-2,4,6-trihydroxy-3,5-dimethoxycyclohexyl]oxy}benzoate

C31H46O13 (626.2938)

(1r,2s,5r,6r,10s,13r,14s,16s)-16-[(1s)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 2-methylbut-2-enoate

C36H50O9 (626.3455)

(1s,4s,9r,12s,13r,16r,17r)-17-{[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-17-(hydroxymethyl)-12-methyl-8-oxapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-5-en-7-one

C31H46O13 (626.2938)

(8ar,10ar)-5-{2-[(8ar,10ar)-2-hydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl]ethyl}-2-hydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

C40H50O6 (626.3607)

(2z)-4-[(1r,2r,15s,16r,17r,19s)-5-[(2s)-2,3-dihydroxy-3-methylbutyl]-12-hydroxy-16-methoxy-8,8,21,21-tetramethyl-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

C34H42O11 (626.2727)

(4ar,5s,6r,8s,8ar)-5-[(3as,6ar)-5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl (2s,3r)-3-(acetyloxy)-2-methylbutanoate

C31H46O13 (626.2938)

(1r,2s,5r,6r,10r,13r,14s,16s)-16-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl (2e)-2-methylbut-2-enoate

C34H42O11 (626.2727)

(1r,2r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-1,9,11,16-tetramethyl-8-[(3s)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

6-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl 5,6,8a-trimethyl-5-[2-(5-oxo-2h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylate

C31H46O13 (626.2938)

(1r,2r,4r,6s,8r,11r,12s,13s,16r,17s,19r,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H46O10 (626.3091)

(1s,3r,4s,5s,9r,13s,14r)-3-[(2s,5s)-5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-[(1r)-1-hydroxyethyl]-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione

C32H47ClO10 (626.2858)

(5s,6r)-6-[(1s,3as,5as,7r,8r,9ar,9br,11ar)-3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(benzoyloxy)-6-hydroxy-2-methylheptan-2-yl acetate

C36H50O9 (626.3455)

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-11-en-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C33H42N2O10 (626.2839)

butyl 6-[11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C36H50O9 (626.3455)

(2s)-5-carbamimidamido-2-({[(2s,4s)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl]-4-methylpyrrolidin-2-yl](hydroxy)methylidene}amino)pentanoic acid

C31H42N6O8 (626.3064)

(1s,2r,3r,4s,5s,6s)-2,3,5-trihydroxy-4,6-dimethoxycyclohexyl 3,5-bis(3-methylbut-2-en-1-yl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoate

C31H46O13 (626.2938)